pharmaphorum May 23, 2024
Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range of diseases, including IgA nephropathy (IgAN).
The $1.8 billion deal – which comes just weeks after Biogen chief executive Chris Viehbacher said the company wasn’t expecting to sign any large deals this year in its first-quarter results update – breaks down to an upfront payment of $1.15 billion, with another $650 million in milestones tied to felzartamab’s development.
Felzartamab is an anti-CD38 antibody that HI-Bio licensed in 2022 from German biotech MorphoSys, which is in the process of being acquired by Swiss pharma group Novartis and holds a 15% stake in the South San...
Today's Sponsors
Today's Sponsor